Study S000580

A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Japanese Adult Participants With Obesity Disease

ClinicalTrials.gov record Study Protocol: Amendment (b) (PDF)Study Protocol: Errata to Amendment (b) (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT05931380
Acronym: ATTAIN-J
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 238
Start: 2023-07-31
Primary completion: 2025-06-19
Lead sponsor: Eli Lilly and Company
Conditions: Obesity
Interventions: DRUG:Orforglipron; DRUG:Placebo
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: OTHER:J2A-JE-GZPD

Registered primary outcomes

Percent Change From Baseline in Body Weight at Week 72 [Baseline, Week 72]
Percentage of Participants Who Achieved With Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline [Baseline to Week 72]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.